gs9674

Taminadenant, also known as PBF-509 and NIR-178, is a potent and orally active adenosine A2A receptor antagonist with potential antineoplastic activity. PBF-509 selectively binds to and inhibits A2AR expressed on T lymphocytes. This abrogates the adenosine A2AR-mediated inhibition of T-lymphocytes and activates a T-cell-mediated immune response against tumor cells, thereby reducing proliferation of susceptible tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often produced in excess by cancer cells.

Cilofexor inhibits binding of a synthetic peptide, Cilofexor is a farnesoid X receptor (FXR) agonist.